How AI Search Is Recommending ED Treatment Pills

The ED treatment category is no longer only being shaped by brand awareness, paid acquisition, or traditional search visibility. In the uploaded LLM Authority Index benchmark, the most commercially meaningful AI discovery moments were pricing and evaluation prompts: buyers asking what BlueChew costs, what Ro costs, how Ro Sparks is priced monthly, and whether telehealth treatment models feel affordable enough to consider.

That changes the category’s visibility problem. A company can be widely known in the consumer market and still fail to appear when AI systems are summarizing subscription costs, monthly plans, medication options, and telehealth affordability. In this dataset, Ro, Sesame, and BlueChew surfaced most often inside the observed pricing cluster, while Hims showed no meaningful presence in this specific pricing-oriented prompt environment.

Key findings

The benchmark analyzed 21 Gemini-led observations across ED treatment and telehealth pricing/evaluation prompts. The strongest public report signal is that pricing, affordability, subscription transparency, and telehealth legitimacy are becoming central to AI-led discovery in this category.

Ro led raw mention presence, appearing in 7 of 21 observations, or 33.33% raw mention presence. Those appearances were neutral pricing references, not valid recommendations.

Sesame followed with 6 of 21 observations, or 28.57% raw mention presence, mostly connected to broader telehealth affordability and marketplace-style healthcare framing.

BlueChew appeared in 4 of 21 observations, or 19.05% raw mention presence, but its visibility was highly concentrated around ED-specific cost prompts such as “How much does BlueChew actually cost?” and “How much does one BlueChew cost?”

Hims had 0% raw mention presence, 0% valid recommendation coverage, 0% top-three recommendation rate, and 0% rank-one rate in this specific uploaded pricing-oriented dataset. That should not be interpreted as a complete absence from all AI discovery, but it is a meaningful gap inside this high-intent prompt set.

What changed in the market

ED treatment discovery used to be dominated by pharmaceutical awareness, search-engine rankings, paid acquisition, and direct-response advertising. AI discovery changes the decision path because buyers can now receive a synthesized answer before clicking into a provider’s site.

Instead of reviewing ten blue links, users are asking AI systems to explain:

pricing structures, subscription plans, dosage tiers, recurring monthly costs, telehealth visit fees, and how different providers compare.

That compresses shortlist formation. AI systems are not merely reflecting whether a brand exists. They are deciding which brands are easy to explain, easy to compare, and easy to position inside a buyer’s affordability question.

The uploaded report frames the category shift clearly: ED treatment AI discovery is being shaped less by generic “best pill” discovery and more by pricing and affordability conversations.

What the benchmark found

The benchmark found a concentrated visibility layer around a small group of telehealth-native brands.

Ro currently appears to hold the strongest pricing-cluster presence in the dataset. Its appearances were tied to cost explanations, Ro Sparks monthly pricing, weight-loss pricing comparisons, and telehealth affordability prompts. The important distinction is that Ro’s visibility was mostly neutral. The dataset did not mark those appearances as positive valid recommendations, but repeated neutral presence during high-intent evaluation moments still matters because the brand becomes part of the buyer’s consideration environment.

Sesame appears to benefit from broad telehealth affordability framing. The benchmark surfaced Sesame in prompts connected to online doctor visit costs, low-cost healthcare access, Costco-linked healthcare programs, and generalized pricing explainers. That suggests Sesame’s AI visibility may be less narrowly ED-specific and more tied to a wider “affordable healthcare marketplace” narrative.

BlueChew showed a more concentrated ED-specific pattern. Its visibility clustered around direct affordability prompts, including “How much does BlueChew actually cost?” and “How much does one BlueChew cost?” The uploaded report notes that these prompts carried some of the largest modeled demand pools in the dataset, making BlueChew’s presence commercially relevant even though it was not marked as valid recommendation capture.

Hims is the clearest warning signal. The brand is highly recognizable in consumer telehealth, but the structured metrics show zero presence in this pricing-oriented benchmark set. That does not prove Hims lacks broader AI visibility. It does suggest that brand awareness alone may not translate into AI-assisted commercial evaluation visibility when buyers ask cost and subscription questions.

Why visibility is not enough

The key finding is not simply that Ro, Sesame, and BlueChew appeared. It is that every tracked company in this dataset had 0% valid recommendation coverage, 0% recommended top-three rate, 0% rank-one rate, and $0 modeled monthly captured recommendation value under the benchmark’s recommendation-credit rules.

That matters because raw mention presence is not the same as recommendation-stage visibility. A brand can be mentioned neutrally in an AI answer without being recommended, ranked, endorsed, or advanced into the buyer’s shortlist. The methodology materials explicitly require this distinction: raw mentions should not be treated as recommendation leadership, and only positive valid recommendations receive recommendation credit.

For ED treatment brands, this creates a more demanding visibility standard. The goal is not just to be named. The goal is to be accurately framed, included in comparison moments, supported by credible source material, and eligible for recommendation credit when the user is ready to choose.

The citation layer

The uploaded extraction data did not include usable citation URLs or source-type breakdowns for this benchmark. That limits any claim about exact source causality. The safe read is not “these sources caused these AI outputs,” but rather: the category needs a stronger public evidence layer around pricing, subscription clarity, medication options, telehealth workflows, and trust signals.

In ED treatment, that citation layer likely needs to include owned pricing pages, medically reviewed explainers, third-party comparison pages, review and reputation sources, telehealth policy explanations, FAQ content, and consistent brand/entity information across the public web.

The current benchmark suggests that AI systems can summarize brands that have extractable pricing narratives. The next question for every ED treatment brand is whether the sources AI systems can access are clear, current, consistent, and persuasive enough to support recommendation-stage answers.

What brands need to fix

ED treatment brands should not treat AI discovery as a generic SEO extension. The prompt environment is more specific than that.

They need clearer pricing architecture: monthly plan costs, dose structures, subscription terms, one-time versus recurring fees, medication options, and what is included in the telehealth workflow.

They need stronger comparison-ready content: pages that explain differences among ED medications, telehealth models, fulfillment options, subscription plans, and affordability tradeoffs without forcing AI systems to infer the structure from scattered pages.

They need better source consistency: the same pricing, product, medical-review, and eligibility information should appear consistently across owned pages and reputable third-party sources.

They need recommendation-stage monitoring: brands should track whether they are merely mentioned, neutrally referenced, positively recommended, ranked in the top three, or absent from high-intent pricing prompts.

They need citation architecture, not just content volume. AI systems need public evidence they can synthesize cleanly.

How CiteWorks Studio helps

1. Map AI recommendation visibility. Track prompts, platforms, company presence, valid recommendations, top-three and rank-one performance, framing, and citation sources.
2. Identify the sources shaping AI answers. Find the editorial, review, forum, government, directory, owned, and search-visible sources that influence brand framing.
3. Build the citation architecture plan. Strengthen the public evidence layer so AI systems have more accurate, consistent, and persuasive source material to synthesize.

Commercial takeaway

The ED treatment category is shifting from brand awareness competition to AI-assisted evaluation competition.

The brands most likely to gain visibility are not necessarily the largest or best known. They are the brands AI systems can explain clearly when buyers ask high-intent questions about pricing, affordability, subscriptions, and telehealth access.

In this benchmark, Ro, Sesame, and BlueChew were the most visible inside the pricing cluster, but none converted that visibility into valid recommendation credit. That is the opportunity: move from neutral presence to recommendation-stage eligibility.

CTA

Want to know how AI systems are recommending your ED treatment brand?

CiteWorks Studio helps healthcare and telehealth brands understand where they appear, where competitors are being surfaced instead, which pricing and comparison prompts carry commercial risk, and what citation architecture needs to change to improve recommendation-stage visibility.

Request an AI Visibility Audit or Citation Architecture Review.